BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34458944)

  • 21. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
    Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
    Tai YC; Domchek S; Parmigiani G; Chen S
    J Natl Cancer Inst; 2007 Dec; 99(23):1811-4. PubMed ID: 18042939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    Calip GS; Kidd J; Bernhisel R; Cox HC; Saam J; Rauscher GH; Lancaster JM; Hoskins KF
    Breast Cancer Res Treat; 2021 Jan; 185(1):195-204. PubMed ID: 32918117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case.
    Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Cioffi M; Molinari AM
    Eur J Med Genet; 2020 Jun; 63(6):103883. PubMed ID: 32058061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Male breast cancer: history, epidemiology, genetic and histopathology].
    Leinung S; Horn LC; Backe J
    Zentralbl Chir; 2007 Oct; 132(5):379-85. PubMed ID: 17907078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological analysis of 38 male patients diagnosed with breast cancer.
    Sahin SI; Balci S; Guler G; Altundag K
    Breast Dis; 2024; 43(1):1-8. PubMed ID: 38363600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.
    Miolo G; Puppa LD; Santarosa M; De Giacomi C; Veronesi A; Bidoli E; Tibiletti MG; Viel A; Dolcetti R
    BMC Cancer; 2006 Jun; 6():156. PubMed ID: 16764716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
    Haraldsson K; Loman N; Zhang QX; Johannsson O; Olsson H; Borg A
    Cancer Res; 1998 Apr; 58(7):1367-71. PubMed ID: 9537231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.
    Gilbert SF; Soliman AS; Karkouri M; Quinlan-Davidson M; Strahley A; Eissa M; Dey S; Hablas A; Seifeldin IA; Ramadan M; Benjaafar N; Toy K; Merajver SD
    Breast Dis; 2011; 33(1):17-26. PubMed ID: 22142662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
    Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
    Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I
    Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
    Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
    Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PML protein expression in hereditary and sporadic breast cancer.
    Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
    Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    Gargiulo P; Pensabene M; Milano M; Arpino G; Giuliano M; Forestieri V; Condello C; Lauria R; De Placido S
    BMC Cancer; 2016 Jul; 16():375. PubMed ID: 27377827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.